Conexxence®▼

(Denosumab)

For Republic of Ireland healthcare professionals only. This content contains promotional and brand information.

Scroll down for Conexxence prescribing information and further product details. For adverse event reporting see bottom of webpage.

Conexxence 60 mg solution for injection in pre-filled syringe. Each pre-filled syringe contains 60 mg of denosumab in 1 mL of solution.

For the Republic of Ireland, the SmPC and Patient Leaflets are located on the Medicines.ie | Reliable & Accurate Online Medicines Information (medicines.ie)

Note: by clicking the link you will leave the Fresenius Kabi Ireland website and be directed to the medicines.ie website.

Please note that product images are for illustrative purposes only and labelling on products may appear differently.

Product Image Sizing FK website - conexxence

Filename: Conexxence Prescribing Information.pdf
Size: 210 KB
Format: pdf

Conexxence Prescribing Information.pdf

Details

Indication

Below are the therapeutic indications for Conexxence 60 mg solution for injection in pre-filled syringe.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women denosumab significantly reduces the risk of vertebral, non-vertebral and hip fractures.

Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, denosumab significantly reduces the risk of vertebral fractures.

Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.

Adverse events should be reported.

Reporting forms and information can be found at:

www.hpra.ie/homepage/about-us/report-an-issue

Adverse events should also be reported to Fresenius Kabi Limited, Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0) 800 090 2513

Job code: IE-CON-2600003

Date of preparation: April 2026